Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Study of PARP Inhibition and Check Point-inhibition Immunotherapy With Concurrent Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic or Advanced Sarcoma

NCT06074692 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06074692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06074692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Study of PARP Inhibition and Check Point-inhibition Immunotherapy With Concurrent Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic or Advanced Sarcoma
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2023
Completion date
December 30, 2026
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma, sarcoma of bone, sarcoma,soft tissue